Contineum Therapeutics (CTNM) Income Statement: Revenue & Earnings

Contineum Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Contineum Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Revenue & Gross Profit
Revenue	0.00	50.00	0.00	0.00
Cost of Revenue	0.26	0.00	0.00	0.00
Gross Profit	-0.26	50.00	0.00	0.00
Operating Expenses
Research & Development	38.42	27.60	16.89	22.36
Selling, General & Administrative	12.47	6.32	5.83	6.29
Operating Expenses	50.89	33.92	22.72	28.65
Operating Income	-50.89	16.08	-22.72	-28.65
Other Income/Expense
Interest Income	8.91	4.61	0.76	0.08
Interest Expense	0.00	0.21	0.39	-0.33
Other Income/Expense	-0.27	2.70	-1.91	-0.10
Income
Income Before Tax	-42.26	23.17	-24.25	-29.00
Income Tax Expense	0.00	0.45	0.00	0.00
Net Income	-42.26	22.72	-24.25	-29.00
Net Income - Continuous Operations	-42.26	22.72	-24.25	-29.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-42.00	23.57	-23.54	-28.32
EBIT	-42.26	23.38	-23.87	-28.65
Depreciation & Amortization	0.26	0.20	0.33	0.33
Earnings Per Share
Basic EPS	-2.00	1.00	-1.00	-14.00
Diluted EPS	-2.00	1.00	-1.00	-14.00
Basic Shares Outstanding	19.35	27.06	16.67	2.11
Diluted Shares Outstanding	19.35	27.06	17.76	2.11